BIMZELX: The first and only licensed selective IL-17A and IL-17F inhibitor for moderate-to-severe plaque psoriasis1-3
BIMZELX is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.1
NICE recommendation applies to severe disease (PASI ≥ 10 or DLQI > 10) and when the disease has not responded to other systemic treatments, or when they are contraindicated or not tolerated.2
EXPLORE THE STORIES
- Bimzelx Summary of Product Characteristics.
- National Institute for Health and Care Excellence. 2021. Final Appraisal Document. Bimekizumab for treating moderate to severe plaque psoriasis.
- Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273)487-498.
Report adverse events
Help us to grow our resource the way you want it to grow.
Date of preparation: August 2021